Organisation paid for research Program year 2025 Source: CMS Open Payments

Skin Sciences, PLLC

Neither a doctor nor a teaching hospital

Research payments

$1,065,320

56 payments

Through program year 2025, Skin Sciences, PLLC is reported as receiving $1,065,320 in research payments, across 56 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,631 2
2024 Research $118,475 7
2023 Research $182,871 16
2022 Research $155,856 12
2021 Research $407,987 11
2020 Research $195,132 6
2019 Research $1,367 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $575,021 21 payments
  2. E.R. Squibb & Sons, L.L.C. $158,569 12 payments
  3. Almirall LLC $133,000 5 payments
  4. Bausch Health US, LLC $64,914 2 payments
  5. Mayne Pharma Inc. $57,091 2 payments
  6. Arcutis Biotherapeutics, Inc. $41,149 11 payments
  7. Mindera Corp $34,210 1 payment
  8. Amgen Inc. $1,367 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Atopic Dermatitis $250,258 4 payments
  2. A patient preference study comparing two CAL/BDP fixed dose combinations used for the topical treatment of plaque psoriasis, one formulated as a cream Wynzora and the other as a foam Enstila $100,000 2 payments
  3. A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $94,608 3 payments
  4. An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-To-Severe Atopic Dermatitis $92,851 3 payments
  5. Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis $75,005 5 payments
  6. A Phase 3, 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis $51,970 2 payments
  7. A Multicenter, Randomized, Placebo-Controlled Study Evaluting the Efficacy and Safety of Deucravacitinib in Patients With Moderate to Severe Scalp Psoriasis $47,911 3 payments
  8. Efficacy and Safety of of Cabtreo Topical Gel in Treatment of Truncal Acne Vulgaris $35,640 1 payment
  9. MATCH Study $34,210 1 payment
  10. A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) $30,502 2 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $34,210 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record